Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2013

View Archived Issues

A modified antibody treatment to prevent fetal death via alloimmunization in the mother

Preclinical evaluation of cell therapy to improve cognitive function after brain irradiation

Uncovering the role of epigenetic readers on gene transcription during heart failure pathogenesis

Patrys advances phase I/IIa trial of PAT-SM6 in MM to final patient group

Sucampo reports topline results from phase Ia trials of cobiprostone and SPI-3608

A.P. Pharma plans to change name and list common stock on NASDAQ

New protein Wnt inhibitors disclosed by Merck KGaA and Cancer Research UK

Onyx and Idis partner to launch carfilzomib managed access program in Europe

Bayer Intellectual Property discloses novel GnRH receptor antagonists

Synergy Pharmaceuticals to spin-off FV-100 assets

Intratumoral CVA21 shows safety and efficacy in phase II melanoma trial

FDA approves Alere Determine HIV-1/2 Ag/Ab Combo test

Epistem receives grant for point-of-care hepatitis C assays

Scripps receives National Institute on Aging grant to study human aging process

Suven Life Sciences characterizes agents acting on serotonin receptors for Alzheimer's disease

Quest Diagnostics launches opioid therapy genetic test

Rosetta Genomics and Tel Aviv University's Ramot receive cancer grant

Japanese authorities classify Evolva's resveratrol as non-drug food supplement

Aradigm receives NIH grant for gastroesophageal reflux aspirations

Prostate cancer research collaboration unites Berg with the U.S. Department of Defense

Stem Cell Therapeutics enters option agreement to license prostate cancer stem cell assets

NWBio receives clearance in Germany to proceed with phase III DCVax-L trial

Bio-Path's lead antisense therapeutic effective in blood cancers

Nuevolution, Howard Hughes Medical Institute, Lexicon and Duke University form collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...